The efficacy of passive therapeutic antibodies has been improved by covalently linking them to synthetic cytotoxic molecules to yield ADCs, which are now successful for the treatment of several forms of cancer, including CD30+ lymphoma and HER2+ breast cancer [24, 25]. This evidence concerns the gene ERBB2 and cancer.